$AB

AB Announces June 30, 2026 Assets Under Management

AllianceBernstein (NYSE: AB) reported preliminary assets under management of $905 billion at June 30, 2026, up from $899 billion at May end. The rise was attributed mainly to firmwide net inflows, including a large low-fee passive fixed income mandate, with markets having a neutral impact. For Q2 ended June 30, net inflows were $0.7 billion.

Original reporting
Published Jul 13, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
$AB
Bullish
medium confidence
Mentioned
$AB
Relevance
5/10
alphai data visualization · based on prnewswire.com
Decision brief

The 30-second read

$ABBullishLow
01

Why it matters

The key new information is the preliminary AUM level at June 30, 2026 and the stated drivers (net inflows, including a large low-fee passive fixed income mandate) plus preliminary Q2 net inflows of $0.7B.

02

Market read

Traders may use the AUM and net inflow figures as a near-term sentiment check, but it is not a full earnings or guidance catalyst.

03

What to watch

The release is preliminary and does not quantify investment performance, fee rate changes, or sustainability of the “large low-fee passive fixed income mandate,” which could cap valuation impact.

Relevance 5/10Novelty 5/10Timing: after-hours, July 13, 2026 AUM update for end of June

Background

AllianceBernstein (AB) is an investment manager; the company periodically discloses AUM and net flow trends as operating metrics.

Company-level read

Ticker impact

$ABBullishMedium confidence
Context

AllianceBernstein reported preliminary AUM rising to $905B at end of June 2026 from $899B at end of May, driven by net inflows.

Expected impact

Likely limited near-term impact unless investors focus on sustained inflow momentum beyond the preliminary quarter figure.

Evidence & confidence

The release provides specific AUM and net inflow figures, but it is not earnings, guidance, or a new operational catalyst; it is a monthly/quarterly preliminary update.

Market effects

Adds a datapoint on asset manager flow resilience, particularly passive fixed income demand.

No explicit regional breakdown beyond distribution channels; likely minimal.

Limited global read-through because the update is firm-specific and preliminary.

Counterpoint

AUM growth is small ($6B) and attributed to inflows with “largely neutral” market impact, so it may not signal improving investment performance or future fee growth.

Key entities

  • AllianceBernstein L.P.

    Reported preliminary firmwide AUM of $905B at end of June 2026 and preliminary Q2 net inflows of $0.7B.

  • AllianceBernstein Holding L.P.

    Co-announced the AUM update alongside AB.

Related articles

$ABMedAI 8/10

AB Science raises EUR 14.2m to fund masitinib Phase III, AB8939

AB Science (Euronext Paris: AB) raised EUR 14.2m via a private placement to fund early steps of a strategic plan due in September. The issue created 23.28m new shares; an existing long-term investor provided EUR 12m. Proceeds target AB8939 in AML and masitinib Phase III in ALS. Cash is about EUR 23m, covering needs beyond 12 months.

$ABMed

AllianceBernstein Holding L.P. Q2 2026 Earnings Call Summary

Strategic Execution and Platform Scaling Achieved record AUM of $905 billion, driven by a return to positive organic growth and the strongest gross sales quarter in five years. Reached the $90 billion to $100 billion private markets AUM target more than a year ahead of schedule, validating a multi-year investment strategy in corporate lending and real estate debt.

$ABMed

AllianceBernstein Holding LP (AB) Q2 2026 Earnings Call Highlights: Record AUM

AllianceBernstein (AB) discussed Q2 2026 earnings call topics, including expectations for the Equitable Corebridge merger to add about $100B of AUM over a couple of years, with combined general account assets around $350B and separate around $200B. Management cited resilient private wealth adviser productivity, reduced expense guidance by $5-10M, and demand shifts in U.S. taxable fixed income.

$ABMedAI 8/10

Advanced Bionics Receives FDA Approval for Expanded Cochlear Implant Candidacy Criteria in SSD and AHL

Advanced Bionics, a Sonova brand, said the US FDA approved expanded indications for its cochlear implant systems for single-sided deafness (SSD) and asymmetric hearing loss (AHL). The criteria broaden adult and pediatric eligibility, with company-cited research estimating 271,000 to 345,000 US adults with SSD and only 2.1% using CIs among eligible patients.

$ABMed

ALLIANCEBERNSTEIN HOLDING L.P. (AB): Results of Operations and Financial Condition

ALLIANCEBERNSTEIN HOLDING L.P. (AB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.01 2 a2q26earningsrelease.htm EX-99.01 2Q26 RELEASE Document Ioanis Jorgali, Investors 629.213.6139 ioanis.jorgali@alliancebernstein.com Carly Symington, Media 629.213.5568 carly.symington@alliancebernstein.com ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES SECOND QUARTER RESULTS

$ROIVMedAI 8/10

What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV)

Roivant Sciences (ROIV) and Priovant Therapeutics launched Lisraya, a $35,000/month dermatomyositis treatment, post-FDA approval. The drug's high price and small patient population present challenges, but its immediate launch and long exclusivity may drive adoption. ROIV owns 71% of Priovant, making Lisraya's success crucial for its financial outlook.